


27th November 2025



Tregem Biopharma Co., Ltd.
448-5 Kajiicho, Kawaramachi-dori, Imadegawa-
sagaru, Kamigyo-ku, Kyoto City
President and CEO Honoka Kiso
info@toregem.co.jp

Notification of receipt of response regarding Pre -IND meeting with the US FDA

Tregem Biopharmaceuticals Inc. (Kyoto City, President and CEO: Honoka Kiso; hereinafter referred to as "Tregem") has been holding pre-IND meetings with the U.S. Food and Drug Administration (FDA) for the U.S. development of an antibody drug (development code: TRG-035) for congenital tooth agenesis.

We are pleased to announce that we have now received an official response from the FDA.

We are developing TRG-035 for the treatment of congenital tooth agenesis in Japan, and have completed Phase I clinical trials, confirming its safety.

In other hand, in preparation for conducting clinical trials in the United States, we held a Pre-IND meeting to confirm the FDA's position.

Based on the response received from the FDA, we were able to obtain important knowledge for future clinical trials in the US, such as:

- FDA's position on clinical trial design for congenital tooth agenesis in the United States.
- How can the data from the Phase I trials conducted in Japan be utilized in development in the US.
- Suggestions for development strategies targeting children.

The unmet medical needs related to congenital tooth agenesis are a common issue not only in Japan but also in countries around the world, including the United States.

We have completed the Pre-IND meeting as the first step in global development, we will continue to work as a company to deliver the USAG-1 antibody, the world's first regenerative drug discovery seed, as a treatment for congenital tooth agenesis to patients around the world as soon as possible.

[About TRG-035]

TRG-035 is the world's first antibody drug that neutralizes the protein USAG-1, which inhibits tooth development. This antibody is expected to activate dormant tooth germs and promote the eruption of new teeth.

Its efficacy has been confirmed in animal models. For the clinical part, phase I clinical trials have now been completed in Japan.

Drug development for congenital tooth agenesis was selected for the Japan Agency for Medical Research and Development (AMED)'s "Drug Discovery Venture Ecosystem Strengthening Project (Public Call for Drug Discovery Ventures)" in June 2024*.

*: Supported by AMED Project Number 25qfb127013j0002 (Subsidy Project Name: "Development of a new antibody drug to regenerate missing teeth in patients with congenital tooth agenesis").

[About congenital tooth agenesis]

Congenital tooth agenesis is defined as the absence of even a single tooth at birth, regardless of tooth type. Individuals with congenital anodontia experience toothlessness from early childhood, a period of jawbone development, making them difficult candidates for dentures or dental implants.

In addition, this led to oral frailty during the growth period, which can have a negative impact on nutritional intake and growth.

Because teeth are missing during the growth period, the jawbone that supports the teeth also atrophies, and in cases where multiple teeth are missing, long-term specialized treatment, including jawbone reconstruction, is required after adulthood.

The only existing treatment available is replacement treatment using dentures or dental implants after reaching adulthood, and there is a strong desire for the development of tooth regeneration therapy as a radical treatment.

【About Toregem BioPharma Co., Ltd. 】

As a bio-venture company originating from Kyoto University, we are conducting research and development of a tooth regeneration treatment called "tooth regrowth medicine."

In particular, we aim to provide groundbreaking treatments for patients suffering from tooth loss, such as congenital and acquired tooth agenesis.

We are currently conducting research and clinical trials with the aim of commercializing the "teething medicine," and in the future we are also considering developing a treatment that can also treat acquired tooth loss caused by tooth cavities and periodontal disease.

We aim to become a comprehensive pharmaceutical research and development manufacturer in the dental field, and contribute to people's health and happiness by providing therapeutic drugs in this field.

- Establishment date: May 12, 2020
- Address: 448-5 Kajiicho, Kawaramachi-dori Imadegawa-sagaru, Kamigyo-ku, Kyoto 602-0841
- Representative: Honoka Kiso
- Business description: Development of dental regenerative medicine
- Official website: <https://toregem.co.jp/>